vs
Side-by-side financial comparison of JOINT Corp (JYNT) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $15.2M, roughly 1.3× JOINT Corp). JOINT Corp runs the higher net margin — 6.5% vs -20.4%, a 27.0% gap on every dollar of revenue. On growth, Sight Sciences, Inc. posted the faster year-over-year revenue change (6.9% vs 3.1%). JOINT Corp produced more free cash flow last quarter ($334.7K vs $-2.0M). Over the past eight quarters, Sight Sciences, Inc.'s revenue compounded faster (2.9% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
JYNT vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $20.4M |
| Net Profit | $991.1K | $-4.2M |
| Gross Margin | 81.4% | 87.3% |
| Operating Margin | 4.9% | -18.0% |
| Net Margin | 6.5% | -20.4% |
| Revenue YoY | 3.1% | 6.9% |
| Net Profit YoY | 5510.5% | 64.9% |
| EPS (diluted) | $0.06 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | $20.4M | ||
| Q3 25 | $13.4M | $19.9M | ||
| Q2 25 | $13.3M | $19.6M | ||
| Q1 25 | $13.1M | $17.5M | ||
| Q4 24 | $14.7M | $19.1M | ||
| Q3 24 | $30.2M | $20.2M | ||
| Q2 24 | $30.3M | $21.4M | ||
| Q1 24 | $29.7M | $19.3M |
| Q4 25 | $991.1K | $-4.2M | ||
| Q3 25 | $855.0K | $-8.2M | ||
| Q2 25 | $93.4K | $-11.9M | ||
| Q1 25 | $967.8K | $-14.2M | ||
| Q4 24 | $17.7K | $-11.8M | ||
| Q3 24 | $-3.2M | $-11.1M | ||
| Q2 24 | $-3.6M | $-12.3M | ||
| Q1 24 | $947.0K | $-16.3M |
| Q4 25 | 81.4% | 87.3% | ||
| Q3 25 | 80.1% | 86.4% | ||
| Q2 25 | 79.1% | 84.8% | ||
| Q1 25 | 77.3% | 86.2% | ||
| Q4 24 | 78.4% | 86.8% | ||
| Q3 24 | 90.7% | 83.9% | ||
| Q2 24 | 90.7% | 85.8% | ||
| Q1 24 | 90.9% | 85.5% |
| Q4 25 | 4.9% | -18.0% | ||
| Q3 25 | 1.2% | -39.7% | ||
| Q2 25 | -8.6% | -59.6% | ||
| Q1 25 | -5.2% | -79.2% | ||
| Q4 24 | 5.5% | -62.5% | ||
| Q3 24 | -1.6% | -55.7% | ||
| Q2 24 | -5.9% | -59.2% | ||
| Q1 24 | -1.4% | -76.4% |
| Q4 25 | 6.5% | -20.4% | ||
| Q3 25 | 6.4% | -41.0% | ||
| Q2 25 | 0.7% | -61.0% | ||
| Q1 25 | 7.4% | -80.8% | ||
| Q4 24 | 0.1% | -62.1% | ||
| Q3 24 | -10.5% | -54.9% | ||
| Q2 24 | -11.9% | -57.7% | ||
| Q1 24 | 3.2% | -84.4% |
| Q4 25 | $0.06 | $-0.07 | ||
| Q3 25 | $0.06 | $-0.16 | ||
| Q2 25 | $0.01 | $-0.23 | ||
| Q1 25 | $0.06 | $-0.28 | ||
| Q4 24 | $0.01 | $-0.23 | ||
| Q3 24 | $-0.21 | $-0.22 | ||
| Q2 24 | $-0.24 | $-0.25 | ||
| Q1 24 | $0.06 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $15.1M | $63.9M |
| Total Assets | $61.0M | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $92.0M | ||
| Q3 25 | $29.7M | $92.4M | ||
| Q2 25 | $29.8M | $101.5M | ||
| Q1 25 | $21.9M | $108.8M | ||
| Q4 24 | $25.1M | $120.4M | ||
| Q3 24 | $20.7M | $118.6M | ||
| Q2 24 | $17.5M | $118.2M | ||
| Q1 24 | $18.7M | $127.3M |
| Q4 25 | — | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $15.1M | $63.9M | ||
| Q3 25 | $22.7M | $64.3M | ||
| Q2 25 | $23.2M | $70.0M | ||
| Q1 25 | $22.8M | $77.6M | ||
| Q4 24 | $20.7M | $87.5M | ||
| Q3 24 | $20.5M | $95.0M | ||
| Q2 24 | $23.2M | $101.6M | ||
| Q1 24 | $26.2M | $109.2M |
| Q4 25 | $61.0M | $115.3M | ||
| Q3 25 | $69.4M | $116.3M | ||
| Q2 25 | $73.2M | $122.0M | ||
| Q1 25 | $80.1M | $129.7M | ||
| Q4 24 | $83.2M | $142.8M | ||
| Q3 24 | $79.6M | $143.6M | ||
| Q2 24 | $82.4M | $149.7M | ||
| Q1 24 | $85.7M | $155.6M |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-1.8M |
| Free Cash FlowOCF − Capex | $334.7K | $-2.0M |
| FCF MarginFCF / Revenue | 2.2% | -9.7% |
| Capex IntensityCapex / Revenue | 9.9% | 0.8% |
| Cash ConversionOCF / Net Profit | 1.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-1.8M | ||
| Q3 25 | $1.8M | $-8.7M | ||
| Q2 25 | $868.6K | $-7.5M | ||
| Q1 25 | $-3.7M | $-11.6M | ||
| Q4 24 | $9.4M | $-3.5M | ||
| Q3 24 | $3.4M | $362.0K | ||
| Q2 24 | $-973.5K | $-9.5M | ||
| Q1 24 | $2.8M | $-9.8M |
| Q4 25 | $334.7K | $-2.0M | ||
| Q3 25 | $1.5M | $-8.9M | ||
| Q2 25 | $363.6K | $-7.8M | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $8.2M | $-3.6M | ||
| Q3 24 | $3.2M | $311.0K | ||
| Q2 24 | $-1.2M | $-9.5M | ||
| Q1 24 | $2.4M | $-9.9M |
| Q4 25 | 2.2% | -9.7% | ||
| Q3 25 | 10.9% | -44.7% | ||
| Q2 25 | 2.7% | -39.6% | ||
| Q1 25 | -30.8% | — | ||
| Q4 24 | 55.9% | -18.9% | ||
| Q3 24 | 10.6% | 1.5% | ||
| Q2 24 | -4.1% | -44.7% | ||
| Q1 24 | 8.1% | -51.4% |
| Q4 25 | 9.9% | 0.8% | ||
| Q3 25 | 2.4% | 0.9% | ||
| Q2 25 | 3.8% | 1.1% | ||
| Q1 25 | 2.5% | 0.0% | ||
| Q4 24 | 8.1% | 0.7% | ||
| Q3 24 | 0.8% | 0.3% | ||
| Q2 24 | 0.9% | 0.4% | ||
| Q1 24 | 1.3% | 0.6% |
| Q4 25 | 1.86× | — | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
